08:26 EDT AbbVie backs FY24 adjusted EPS view $10.71-$10.91, consensus $10.87
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Completes Acquisition of Cerevel Therapeutics
- AbbVie price target raised to $210 from $195 at Truist
- AbbVie announces European Commission approval of Skyrizi
- AbbVie price target raised to $200 from $187 at Barclays
- ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales